As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Corporate Overview

IsoTopics™ – October 2019

Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics

Galvez, L.; Rusz, M.; Schwaiger-Haber, M.; et al.

Oxaliplatin is a chemotherapy drug administered to aid treatment of metastatic colorectal cancer. Despite its regularity, the impact of this metallodrug on drug uptake/distribution and the metabolome remains unclear. In an effort to address this, Koellensperger and colleagues developed an integrated metallomics/metabolomics method for evaluating sensitive/resistant human colon cancer cell models. This approach involved adding a U-13C metabolite yeast extract (ISO1) at the extraction stage for normalization and improved repeatability, with split analysis for platinum (by ICP-MS) and metabolite (by HILIC-MS/MS) measurement. The combined results shed light on oxaliplatin resistance mechanisms, with future studies needed to investigate the effects of inhibiting fatty acid oxidation on drug sensitivity/resistance.

Read article 


Stable Isotope Newsletters | Cambridge Isotope Laboratories
stable isotope, stable isotope labeled compounds, environmental contaminant standards
CIL has been ready to help with the analytical standards critical to the task of defining and resolving any major environmental contamination problems.